PLK1 and acute myeloid leukemia: Combined findings from a phase Ib and subsequent phase II trial evaluating the efficacy of onvansertib, a novel and highly specific PLK1 inhibitor, in combination with low-dose cytarabine or decitabine for patients with relapsed or refractory AML demonstrated complete remission in 20% (n = 9/44) of patients (40, 41).